NextCure, Inc.
NXTC
$8.21
-$0.07-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.03% | -12.21% | -16.77% | -24.59% | -21.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.30% | -13.05% | -21.66% | -28.41% | 65.47% |
| Operating Income | 63.30% | 13.05% | 21.66% | 28.41% | -65.47% |
| Income Before Tax | 44.45% | 10.75% | 18.68% | 25.27% | -74.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.45% | 10.75% | 18.68% | 25.27% | -74.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.45% | 10.75% | 18.68% | 25.27% | -74.03% |
| EBIT | 63.30% | 13.05% | 21.66% | 28.41% | -65.47% |
| EBITDA | 63.45% | 10.45% | 20.28% | 28.68% | -68.80% |
| EPS Basic | 75.16% | 60.24% | 52.33% | 34.90% | -70.83% |
| Normalized Basic EPS | 83.63% | 60.24% | 52.33% | 34.90% | -70.83% |
| EPS Diluted | 75.16% | 60.24% | 52.33% | 34.90% | -70.83% |
| Normalized Diluted EPS | 83.63% | 60.24% | 52.33% | 34.90% | -70.83% |
| Average Basic Shares Outstanding | 123.59% | 124.48% | 70.59% | 14.79% | 1.87% |
| Average Diluted Shares Outstanding | 123.59% | 124.48% | 70.59% | 14.79% | 1.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |